Nuvectis Pharma, Inc.
Clinical trials sponsored by Nuvectis Pharma, Inc., explained in plain language.
A biopharmaceutical company developing precision medicines for cancer.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New pill shows promise against tough cancers in early trial
Disease control Recruiting nowThis study tests a new oral drug called NXP900 in people with advanced solid tumors (like lung, kidney, or mesothelioma) that have not responded to standard treatments. The trial has two parts: first, finding the right dose, and then seeing if the drug shrinks tumors. It is a fir…
Phase: PHASE1 • Sponsor: Nuvectis Pharma, Inc. • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New drug combo aims to outsmart resistant lung cancer
Disease control Recruiting nowThis early-phase trial tests a new oral drug called NXP900 combined with the standard drug osimertinib in 18 adults with advanced EGFR-mutated non-small cell lung cancer that has progressed on prior osimertinib. The main goals are to check safety and see if the combination can sh…
Phase: PHASE1 • Sponsor: Nuvectis Pharma, Inc. • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC